Altamira Therapeutics to Participate at RNA Leaders USA Congress
Altamira Therapeutics (Nasdaq: CYTO) will participate in the RNA Leaders USA Congress on October 18-19, 2022, in Boston, MA. Chief Scientific Officer Samuel Wickline, MD, will present their OligoPhore/SemaPhore delivery platform, emphasizing its advantages for siRNA therapeutics. Key benefits include a universal formulation process, extrahepatic delivery with minimal off-target effects, and deep tissue penetration. Altamira aims to out-license this innovative platform to biotech firms and is developing internal programs targeting KRAS-driven cancers and rheumatoid arthritis.
- None.
- None.
HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) --
- Event will be held on October 18-19, 2022 in Boston, MA
- Samuel Wickline, MD, Chief Scientific Officer, to present on the advantages of the OligoPhore/SemaPhore technology, a versatile peptide-based delivery platform for extrahepatic RNA delivery
- The event will provide the Company the opportunity to present its innovative delivery platform and engage with RNA community in science and industry
Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will participate in-person at the RNA Leaders USA Congress being held on October 18-19, 2022 at The Colonnade Hotel in Boston, Massachusetts.
Altamira’s Chief Scientific Officer, Samuel A. Wickline, MD, will be introducing the Company’s flagship OligoPhore/ SemaPhore delivery platform and address the following aspects and advantages of siRNA therapeutics that differentiate the Company’s technology:
- Universal formulation process for any RNA species, single or multiplexed to address one or more signaling pathways simultaneously
- Systemic administration achieving extrahepatic delivery to diverse pathologies, but excluding permeation of normal tissues to limit off-target effects
- Deep penetration into tumor and inflammatory microenvironment
- Extensive and rapid pH-dependent endosomal escape of RNA cargo to promote immediate RNA silencing or enhanced protein expression as needed
- Minimize tissue toxicity and immune reactivity after serial dosing in a multiplicity of disease models
- Adaptable to diverse pathologies with readily exchangeable RNA cargos to counter adaptive disease responses
Altamira aims to become a leading provider of RNA delivery technology through its patented OligoPhore/SemaPhore platform, which it seeks to out-license to biotech and pharma companies for use with their own RNA molecules. In addition, the Company is progressing two internal early-stage programs which utilize the technology: the AM-401 program that targets KRAS-driven cancers and the AM-411 program that focuses on the treatment for rheumatoid arthritis. Both programs shall be out-licensed for later development steps.
About RNA Leaders USA Congress
The RNA Leaders USA Congress focuses on the scientific, clinical and commercial development of RNA therapeutics and vaccines. The event brings together the most senior executives to deliver updates from across the full RNA landscape (RNAi, antisense technologies, small molecule targeting, mRNA and more).
About OligoPhore/SemaPhore
OligoPhore/SemaPhore is a versatile platform for safe and effective delivery of oligonucleotides such as siRNA (small interfering ribonucleic acid) or mRNA (messenger RNA) into target cells. It is based on a proprietary 21-amino acid peptide that can engage any type of RNA in rapid self-assembly into a polyplex. The polyplex has size, charge, and other physical features that allow it to escape hepatic uptake and thus to reach extrahepatic tissues. OligoPhore/SemaPhore protects the RNA payload from degradation in the circulation and allows for rapid cellular uptake, while enabling pH-dependent nucleotide endosomal escape and cytoplasmic delivery. Effective delivery and positive treatment outcomes have been demonstrated in more than 10 murine models of disease for targets in the RAS and NF-κB families, the ETS transcription factor family, and targets in the JNK, TAM, and other signaling pathways.
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq: CYTO) is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne allergens and, where approved, viruses (Bentrio™; commercial) or for the treatment of vertigo (AM-125; post Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). Founded in 2003, it is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/
Forward-Looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2021, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov . Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
FAQ
What is Altamira Therapeutics' involvement in the RNA Leaders USA Congress?
Who will present at the RNA Leaders USA Congress for Altamira Therapeutics?
What technology will Altamira Therapeutics showcase at the event?
What are the advantages of the OligoPhore/SemaPhore platform?
What internal programs is Altamira Therapeutics developing?
